Back

Heart failure & SGLT2: with or without diabetes?

27 August 2018 (13:35 - 13:55)
Organised by:
Congress Presentation Part of: Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited) Treatment ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Introduction - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.
Professor F. Cosentino (Stockholm, SE)
Presentation thumbnail
SGLT2 inhibition in cardiology: what is the profile of benefit? .
Professor N. Marx (Aachen, DE)
Presentation thumbnail
Changing focus in diabetes: From glucose to cardiovascular risk management.
Professor S. Jacob (Villingen, DE)
Presentation thumbnail
Discussion - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.
Professor F. Cosentino (Stockholm, SE)

Access the full session

Session thumbnail
Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

27 August 2018 13:35 CET
You may be interested in
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Which device might help your HFpEF patient?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources